-
Publication Venue For
-
Interventions to improve lung cancer screening among racially and ethnically minoritized groups: A scoping review..
176:46-55.
2023
-
Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study..
175:17-26.
2023
-
First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743..
167:8-16.
2022
-
Time to diagnosis and treatment of lung cancer: A systematic overview of risk factors, interventions and impact on patient outcomes..
166:27-39.
2022
-
Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNA..
165:43-48.
2022
-
Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study..
161:180-188.
2021
-
Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer..
159:56-65.
2021
-
Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538..
156:68-71.
2021
-
Role of dietary carbohydrates on risk of lung cancer..
155:87-93.
2021
-
RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry..
153:90-98.
2021
-
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study..
147:137-142.
2020
-
A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226..
143:1-11.
2020
-
Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer..
141:14-20.
2020
-
Examining the role of access to care: Racial/ethnic differences in receipt of resection for early-stage non-small cell lung cancer among integrated system members and non-members..
125:51-56.
2018
-
Stereotactic body radiation therapy versus sublobar resection for stage I NSCLC..
125:185-191.
2018
-
Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: A national analysis..
115:75-83.
2018
-
Genetic predisposition to lung adenocarcinoma among never-smoking Chinese with different epidermal growth factor receptor mutation status..
114:79-89.
2017
-
Identification of a serum microRNA expression signature for detection of lung cancer, involving miR-23b, miR-221, miR-148b and miR-423-3p..
114:6-11.
2017
-
The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials..
102:21-27.
2016
-
Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer..
98:76-78.
2016
-
Diffuse malignant mesothelioma and synchronous lung cancer: A clinicopathological study of 18 cases..
95:1-7.
2016
-
The impact of tumor size on the association of the extent of lymph node resection and survival in clinical stage I non-small cell lung cancer..
90:554-560.
2015
-
Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups..
90:281-287.
2015
-
Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers..
88:108-111.
2015
-
Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis..
88:85-93.
2015
-
A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy..
86:288-290.
2014
-
Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma..
86:255-261.
2014
-
CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation..
85:152-160.
2014
-
SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines..
85:1-6.
2014
-
Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904..
82:436-440.
2013
-
Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses..
76:478-485.
2012
-
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107)..
76:393-396.
2012
-
Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer..
76:248-252.
2012
-
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy..
75:82-88.
2012
-
Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer..
74:446-450.
2011
-
A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531..
74:258-263.
2011
-
No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis..
72:370-377.
2011
-
Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients..
72:238-243.
2011
-
Effects of aerobic training on oxidative status in postsurgical non-small cell lung cancer patients: a pilot study..
72:45-51.
2011
-
Repressive coping style: relationships with depression, pain, and pain coping strategies in lung cancer outpatients..
71:235-240.
2011
-
Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database..
64:226-231.
2009